Suppliers / Sichuan Qingmu Pharmaceutical

Sichuan Qingmu Pharmaceutical

China 3 employees Updated 9 July 2026

Sichuan Qingmu Pharmaceutical is an API manufacturer based in China. It holds 11 active US drug master files across a filed portfolio of 11 molecules. Its GMP standing is certified by MFDS (Korea). Its most recent recorded inspection, by US FDA, closed on 7 September 2021 as VAI.

11
active US DMFs
0
valid CEPs
1
registered plants 1 with an FDA FEI number
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 7 September 2021 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
China, China 3014747858

What they file, and where

Molecule Regulators Docs
Dabigatran Etexilate US FDA 1
Lemborexant US FDA 1
Lenvatinib US FDA 1
Methylene Blue US FDA 1
Nalmefene US FDA 1
Naloxone US FDA 1
Nicardipine US FDA 1
Rotigotine US FDA 1
Silodosin US FDA 1
Sugammadex US FDA 1
Show all 11 molecules on file
Ticagrelor US FDA 1

Also appears on these molecule pages

Lenvatinib API Methylene Blue API Naloxone API Nicardipine API Rotigotine API Silodosin API Ticagrelor API Sugammadex API Dabigatran Etexilate API

Filings and GMP by regulator

Regulator Filings GMP certificates
MFDS (Korea) None 2

Questions about Sichuan Qingmu Pharmaceutical

Does Sichuan Qingmu Pharmaceutical hold a US DMF or a CEP?
Sichuan Qingmu Pharmaceutical holds 11 active US drug master files. A drug master file is a submission to the FDA describing how an ingredient is made; a CEP is the EDQM's certificate that the substance meets its European Pharmacopoeia monograph. Both are filings rather than approvals.
Is Sichuan Qingmu Pharmaceutical FDA-registered?
One site operated by Sichuan Qingmu Pharmaceutical carries an FDA establishment identifier (FEI), which means it is registered with the FDA as a drug establishment. Registration is not the same as approval or inspection clearance.
How did Sichuan Qingmu Pharmaceutical's last inspection go?
The most recent inspection on record closed on 7 September 2021 as VAI (Voluntary Action Indicated: issues were found but did not warrant regulatory action). 1 inspection is on file.
Where does Sichuan Qingmu Pharmaceutical manufacture?
1 registered site is on record, in China (China). Every site is listed on this page with the register it came from.
What does Sichuan Qingmu Pharmaceutical make?
11 molecules are on record against Sichuan Qingmu Pharmaceutical, including Dabigatran Etexilate, Lemborexant, Lenvatinib and Methylene Blue. Each links through to that molecule's full manufacturer list.
Which regulators recognise Sichuan Qingmu Pharmaceutical's GMP?
Current GMP certificates are on record from MFDS (Korea). GMP recognition covers the manufacturing site, separately from any filing on the substance itself.

Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.

Comparing suppliers?

Choose your molecules and target markets. Sichuan Qingmu Pharmaceutical comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 7 September 2021.

Comparable suppliers

Olon shares 4 molecules MSN Laboratories shares 3 molecules Hetero shares 2 molecules Zhejiang Huahai Pharmaceutical shares 2 molecules Apitoria Pharma shares 1 molecule

Ranked by shared active ingredients where we have them, otherwise by country and comparable credentials.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates